TNF and uveitis: The introduction of the first anti-TNF agent in PsA and SpA is usually a result of clinical worsening of disease activity, resulting in a high expected incidence of uveitis in the first months after treatment start, as suggested by the higher proportion of de novo uveitis compared to recurrent uveitis on qualitative analysis in the first year of treatment (4.71% and 2.77%, respectively).